stockportfolio.pro
Stocks / INVA vs NTLA
INVA vs NTLA
Innoviva, Inc. and Intellia Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Innoviva, Inc. (INVA) | Intellia Therapeutics, Inc. (NTLA) | |
|---|---|---|
| Market cap | $1.7B | $1.7B |
| Revenue (latest FY) | $411.33M | $67.67M |
| Net income (latest FY) | $271.17M | $-412.69M |
| Revenue growth (5y CAGR) | 4.1% | 3.1% |
| Net margin | 65.9% | -609.9% |
| Return on equity | 23.1% | -61.5% |
| P/E ratio | 3.7 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 10 | 0 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open INVA — free Open NTLA — freeFrequently asked questions
Which is bigger, INVA or NTLA?
Innoviva, Inc. is larger by market capitalization — $1.7B versus $1.7B.
Which grows faster, INVA or NTLA?
Over the last five fiscal years, Innoviva, Inc. grew revenue faster — 4.1%/yr versus 3.1%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.